Breast Cancer, Invasive Breast Cancer
Conditions
Keywords
Breast Cancer, Node Positive Breast Cancer, Sentinel Lymph Node Biopsy, Breast Surgery, Axillary Lymph Node Dissection, Neoadjuvant Chemotherapy
Brief summary
Title of Study: Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer. Objectives of the study: Primary objective 1\. Evaluate the accuracy of sentinel node biopsy in breast cancer patients presenting with positive nodal disease, proven by ultrasound guided fine needle aspiration, following neoadjuvant chemotherapy. Secondary objectives 1. Evaluate the technical success of sentinel node biopsy following neoadjuvant chemotherapy. 2. Evaluate the accuracy of clinical examination and ultrasound examination of the axilla in identifying the presence of residual disease in the axilla following neoadjuvant chemotherapy in biopsy proven node positive breast cancer patients. Number of patients: N = 300 Population: Patients with unresected breast cancer that are eligible for neoadjuvant chemotherapy that present with biopsy proven positive axillary nodes. Study duration: From February 2009 to February 2012 - 3 years
Interventions
PROCEDURESentinel Lymph Node Biopsy
Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
Sponsors
Quebec Breast Cancer Foundation
Centre hospitalier de l'Université de Montréal (CHUM)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Conditions for patient eligibility Inclusion criteria: * Patients must be female. * Patients must be 18 years of age or older. * Patients with stage IIA, IIB, IIIA (T1-3 and N1-2) breast cancer. Clinical N0 accepted if biopsy proven node disease. * Patients that have biopsy proven positive axillary disease made by core needle biopsy or fine needle aspiration . * Patients that accept to undergo neoadjuvant chemotherapy; patients are eligible until the day of surgery. * Patients with bilateral breast cancer are eligible. Sentinel node biopsy is allowed on the contralateral breast if there is no disease in the axilla prior to chemotherapy. * Patients that understand, accept and have signed the approved consent form.
Exclusion criteria
* Patients with inflammatory breast cancer. * Patient with stage IIIB, IIIC or IV breast cancer (T4 and N3) Patients with clinical N3 disease are excluded. * Patients that have had previous axillary dissection or an axillary sentinel node biopsy; (patients that have had excisional biopsy or ipsilateral tumorectomy are eligible). * Patients that have had previous radiotherapy to the axillary nodes * Patients that have had mammary reduction * Patients that are medically unfit to receive chemotherapy, as evaluated by the treating physician. * If the injection of blue dye is planned, patients with hypersensitivity or allergy to isosulfan blue, Patent blue or methylene blue or radiocolloid dye are ineligible. * Patients who are pregnant or breast feeding . * Psychiatric or addictive disorders or other conditions that preclude the patient from meeting the study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The false negative rate of sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer. | 4-7 months |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the accuracy of clinical evaluation and ultrasound examination in determining the presence of residual disease following neoadjuvant chemotherapy in biopsy proven node positive breast cancer. | 3-6 months |
| Evaluate the technical success rate of sentinel node biopsy following neoadjuvant chemotherapy | 4-7 months |
Countries
Canada
Outcome results
None listed